ArticleJournal of experimental & clinical cancer research : CR2014
A four-long non-coding RNA signature in predicting breast cancer survival.
Article in Journal of experimental & clinical cancer research : CR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 148 citations in OpenAlex.
- Integrative single-cell transcriptomics and co-expression network analysis identify SIMALR as a prognostic immune-related lncRNA in breast cancer: in silico analysis and validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- As a novel prognostic model for breast cancer, the identification and validation of telomere-related long noncoding RNA signatures.World journal of surgical oncology · 2024Article
- Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer.Scientific reports · 2024Article
- The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.International journal of molecular sciences · 2023Review
- Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis.Annals of medicine · 2023Review
- lncRNA-disease association prediction based on matrix decomposition of elastic network and collaborative filtering.Scientific reports · 2022Article
- Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty.NPJ precision oncology · 2022Review
- Article
- Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis.Journal of clinical laboratory analysis · 2022Article
- Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis.Journal of healthcare engineering · 2022Article
- Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance.Frontiers in genetics · 2022Review
- Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.Current gene therapy · 2022Review
- Corylin suppresses metastasis of breast cancer cells by modulating miR-34c/LINC00963 target.The Libyan journal of medicine · 2021Article
- A seven-lncRNA signature for predicting prognosis in breast carcinoma.Translational cancer research · 2021Article
- Article
- Long non-coding RNA ROR recruits histone transmethylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression.Journal of translational medicine · 2021Article
- Risk factors associated with major adverse cardiac and cerebrovascular events following percutaneous coronary intervention: a 10-year follow-up comparing random survival forest and Cox proportional-hazards model.BMC cardiovascular disorders · 2021Article
- Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer.Frontiers in genetics · 2021Article
- A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells.PloS one · 2021Article
- A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer.Disease markers · 2021Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany long non-coding RNAs(lncRNAs) have been found to be a good marker for several tumors. Using lncRNA-mining approach, we aimed to identify lncRNA expression signature that can predict breast cancer patient survival.
methodsWe performed LncRNA expression profiling in 887 breast cancer patients from Gene Expression Omnibus (GEO) datasets. The association between lncRNA signature and clinical survival was analyzed using the training set(n = 327, from GSE 20685). The validation for the association was performed in another three independent testing sets(252 from GSE21653, 204 from GSE12276, and 104 from GSE42568).
resultsA set of four lncRNA genes (U79277, AK024118, BC040204, AK000974) have been identified by the random survival forest algorithm. Using a risk score based on the expression signature of these lncRNAs, we separated the patients into low-risk and high-risk groups with significantly different survival times in the training set. This signature was validated in the other three cohorts. Further study revealed that the four-lncRNA expression signature was independent of age and subtype. Gene Set Enrichment Analysis (GSEA) suggested that gene sets were involved in several cancer metastasis related pathways.
conclusionsThese findings indicate that lncRNAs may be implicated in breast cancer pathogenesis. The four-lncRNA signature may have clinical implications in the selection of high-risk patients for adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.